{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:33:36Z","timestamp":1793831616338,"version":"4.6.1"},"reference-count":142,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Overweight and obesity are recognized as a public health crisis and considered a global pandemic. In adults with congenital heart disease (ACHD) it is also considered a growing menace affecting up to half of this population. In ACHD, the negative impact of obesity on cardiovascular outcomes is likely amplified by already present underlying structural and physiological cardiac abnormalities, further increasing the risk of heart failure, arrhythmias, and other cardiovascular complications. As a potentially reversible risk factor, obesity represents a clear target for improving outcomes in this already vulnerable population. While lifestyle interventions remain foundational, the use of anti-obesity medications has expanded rapidly, though evidence in ACHD remains scarce. In this state-of-the-art review, informed by a comprehensive 30-year literature overview and the expertise of an international, multidisciplinary authorship, we provide clinically practical recommendations for the judicious use of anti-obesity therapies in ACHD. This document aims to guide clinicians in real-world decision-making and serve as a foundation for future research at the intersection of obesity and congenital heart disease.<\/jats:p>","DOI":"10.1093\/ehjqcco\/qcag067","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:30:54Z","timestamp":1776166254000},"page":"927-946","source":"Crossref","is-referenced-by-count":2,"title":["Anti-obesity medications in adults with congenital heart disease: a comprehensive review and expert clinical recommendations"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-3060","authenticated-orcid":false,"given":"Panagiota","family":"Mitropoulou","sequence":"first","affiliation":[{"name":"Cardiology Department, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Prok\u0161elj","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Ljubljana, 10 000 Ljubljana ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Jane\u017e","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , 10 000 Ljubljana ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Riesgo","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplant, Royal Brompton and Harefield Hospitals , Harefield UB9 6JH ,","place":["UK"]},{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Chelsea and Westminster Healthcare NHS Trust , London SW10 9 NH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Juri\u0107","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb , 10 000 Zagreb ,","place":["Croatia"]},{"name":"INSERM, PARCC, Paris Institute for Transplantation and Organ Regeneration, Universit\u00e9 de Paris Cit\u00e9 , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimiro","family":"Vida","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua , 35218 Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Gatzoulis","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, Guys and St Thomas\u2019 NHS Trust , Sydney Street, London SW3 6NP ,","place":["UK"]},{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-8156","authenticated-orcid":false,"given":"Margarita","family":"Brida","sequence":"additional","affiliation":[{"name":"Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, Guys and St Thomas\u2019 NHS Trust , Sydney Street, London SW3 6NP ,","place":["UK"]},{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]},{"name":"Department of Medical Rehabilitation, Medical Faculty, University of Rijeka , 51000 Rijeka ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026091606032470600_qcag067-B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.15.1861","article-title":"Excess deaths associated with underweight, overweight, and obesity","volume":"293","author":"Flegal","year":"2005","journal-title":"JAMA"},{"key":"2026091606032470600_qcag067-B2","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18189931","article-title":"Overweight and obesity in patients with congenital heart disease: a systematic review","volume":"18","author":"Willinger","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026091606032470600_qcag067-B4","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1093\/eurheartj\/ehad570","article-title":"Acquired cardiovascular disease in adults with congenital heart disease","volume":"44","author":"Brida","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B5","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(11)60105-0","article-title":"Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies","volume":"377","author":"The Emerging Risk Factors Collaboration","year":"2011","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1274","article-title":"Is BMI the best measure of obesity?","volume":"360","author":"Adab","year":"2018","journal-title":"BMJ"},{"key":"2026091606032470600_qcag067-B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091606032470600_qcag067-B9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/nu13020498","article-title":"The role of hypothalamic inflammation in diet-induced obesity and its association with cognitive and mood disorders","volume":"13","author":"Dionysopoulou","year":"2021","journal-title":"Nutrients"},{"key":"2026091606032470600_qcag067-B11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1749-6632.2002.tb04294.x","article-title":"Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography","volume":"967","author":"Del Parigi","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2026091606032470600_qcag067-B12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1017\/S104795111400153X","article-title":"Childhood growth patterns following congenital heart disease","volume":"25","author":"Aguilar","year":"2015","journal-title":"Cardiol Young"},{"key":"2026091606032470600_qcag067-B13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.hrtlng.2020.08.020","article-title":"Obesity across the lifespan in congenital heart disease survivors: prevalence and correlates","volume":"49","author":"Jackson","year":"2020","journal-title":"Heart Lung"},{"key":"2026091606032470600_qcag067-B14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001132","article-title":"Metabolic syndrome in adults with congenital heart disease","volume":"5","author":"Deen","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2026091606032470600_qcag067-B16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019942","article-title":"Hepatic steatosis in patients with single ventricle and a fontan circulation","volume":"10","author":"Katz","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B17","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.3030","article-title":"Pulmonary hemodaynamic in obesity","volume":"41","author":"Zhou","year":"2020","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0735-1097(20)31242-0","article-title":"Abnormal diastolic function in obese adults with congenital heart disease","volume":"75","author":"Pan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026091606032470600_qcag067-B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100530","article-title":"Increased prevalence of left ventricular diastolic dysfunction in adults with repaired coarctation of aorta","volume":"28","author":"Egbe","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026091606032470600_qcag067-B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fcvm.2017.00005","article-title":"Assessment of diastolic function in congenital heart disease","volume":"4","author":"Panesar","year":"2017","journal-title":"Front Cardiovasc Med"},{"key":"2026091606032470600_qcag067-B21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/echo.14113","article-title":"Diastolic dysfunction in tetralogy of Fallot: comparison of echocardiography with catheterization","volume":"35","author":"DiLorenzo","year":"2018","journal-title":"Echocardiography"},{"key":"2026091606032470600_qcag067-B22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009618","article-title":"Determinants of left ventricular dysfunction and remodeling in patients with corrected tetralogy of Fallot","volume":"8","author":"Andrade","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101758","article-title":"Diagnosis of diastolic dysfunction in adults with failing fontan circulation","volume":"4","author":"Khayyat","year":"2025","journal-title":"JACC Adv"},{"key":"2026091606032470600_qcag067-B24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/MOH.0b013e3283634443","article-title":"Mechanisms of thrombosis in obesity","volume":"20","author":"Blokhin","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"2026091606032470600_qcag067-B25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032277","article-title":"Impact of obesity on atrial fibrillation pathogenesis and treatment options","volume":"13","author":"Sha","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B26","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1161\/CIRCULATIONAHA.109.866319","article-title":"Atrial arrhythmias in adults with congenital heart disease","volume":"120","author":"Bouchardy","year":"2009","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf784.3219","article-title":"Does obesity impact outcomes in TAVI? A systematic review and meta-analysis","volume":"46","author":"Dexheimer Da Silva","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B28","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9110386","article-title":"A meta-analysis on the impact of high BMI in patients undergoing transcatheter aortic valve replacement","volume":"9","author":"Seo","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026091606032470600_qcag067-B29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.surg.2023.02.001","article-title":"The association between obesity and postoperative outcomes in a broad surgical population: a 7-year American College of Surgeons National Surgical Quality Improvement analysis","volume":"173","author":"Madsen","year":"2023","journal-title":"Surgery"},{"key":"2026091606032470600_qcag067-B30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.116.026778","article-title":"Effect of obesity and underweight status on perioperative outcomes of congenital heart operations in children, adolescents, and young adults: an analysis of data from the society of thoracic surgeons database","volume":"136","author":"O\u2019Byrne","year":"2017","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1017\/S1047951119003329","article-title":"Does obesity affect the short-term outcomes after cardiothoracic surgery in adolescents with congenital heart disease?","volume":"30","author":"Garcia","year":"2020","journal-title":"Cardiol Young"},{"key":"2026091606032470600_qcag067-B32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034871","article-title":"Development and validation of a mortality risk score for repaired tetralogy of Fallot","volume":"13","author":"Mayourian","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International society for heart and lung transplantation guidelines for the evaluation and care of cardiac transplant candidates-2024","volume":"43","author":"Peled","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"2026091606032470600_qcag067-B34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.122.061546","article-title":"Risk of heart failure in congenital heart disease: a nationwide register-based cohort study","volume":"147","author":"Bergh","year":"2023","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B35","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae283","article-title":"International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)","volume":"111","author":"Cohen","year":"2024","journal-title":"Br J Surg"},{"key":"2026091606032470600_qcag067-B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41366-024-01648-7","article-title":"Comparative effectiveness of metabolic and bariatric surgeries: a network meta-analysis","volume":"49","author":"Malik","year":"2025","journal-title":"Int J Obes"},{"key":"2026091606032470600_qcag067-B37","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1038\/s41598-024-57724-5","article-title":"Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis","volume":"14","author":"Pipek","year":"2024","journal-title":"Sci Rep"},{"key":"2026091606032470600_qcag067-B38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026091606032470600_qcag067-B39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3803\/EnM.2020.934","article-title":"Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials","volume":"36","author":"Moon","year":"2021","journal-title":"Endocrinol Metab"},{"key":"2026091606032470600_qcag067-B40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026091606032470600_qcag067-B41","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13792","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus\u2014a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Kommu","year":"2024","journal-title":"Obes Rev"},{"key":"2026091606032470600_qcag067-B42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis","volume":"37","author":"Tan","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"2026091606032470600_qcag067-B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1132004","article-title":"Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026091606032470600_qcag067-B44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"2026091606032470600_qcag067-B46","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2026091606032470600_qcag067-B47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B48","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B49","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009304","article-title":"Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: insights from the EXSCEL trial","volume":"7","author":"Mentz","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B52","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B53","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026091606032470600_qcag067-B55","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B56","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026091606032470600_qcag067-B57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091606032470600_qcag067-B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2026091606032470600_qcag067-B59","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"2026091606032470600_qcag067-B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2026091606032470600_qcag067-B62","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.107.734921","article-title":"Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease","volume":"117","author":"Dimopoulos","year":"2008","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131833","article-title":"Incidence of diabetes mellitus and effect on mortality in adults with congenital heart disease","volume":"401","author":"Bj\u00f6rk","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026091606032470600_qcag067-B64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12883-024-03967-8","article-title":"Risk of stroke in patients with congenital heart disease: a systematic review and meta-analysis","volume":"24","author":"Odat","year":"2024","journal-title":"BMC Neurol"},{"key":"2026091606032470600_qcag067-B65","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag017","article-title":"Heart failure with preserved ejection fraction in adults with congenital heart disease","author":"Maegaard Eriksen","year":"2026","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/CIRCULATIONAHA.120.045597","article-title":"Fontan-associated liver disease: screening, management, and transplant considerations","volume":"142","author":"Emamaullee","year":"2020","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B67","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.jacc.2020.10.035","article-title":"Prognostic role of hepatorenal function indexes in patients with Ebstein anomaly","volume":"76","author":"Egbe","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026091606032470600_qcag067-B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101674","article-title":"Glucagon-like peptide-1 agonist use in adults with congenital heart disease","volume":"4","author":"Thapa","year":"2025","journal-title":"JACC Adv"},{"key":"2026091606032470600_qcag067-B69","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00246-024-03700-9","article-title":"Safety and efficacy of GLP-1 agonists in a cohort of patients with fontan circulation","volume":"46","author":"Freddo","year":"2024","journal-title":"Pediatr Cardiol"},{"key":"2026091606032470600_qcag067-B70","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.cjca.2019.10.002","article-title":"Eisenmenger syndrome: a multisystem disorder\u2014do not destabilize the balanced but fragile physiology","volume":"35","author":"Chaix","year":"2019","journal-title":"Can J Cardiol"},{"key":"2026091606032470600_qcag067-B71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijcard.2018.09.005","article-title":"Depression and anxiety are associated with high health care utilization and mortality among adults with congenital heart disease","volume":"276","author":"Benderly","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026091606032470600_qcag067-B72","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014820","article-title":"Prevalence and prognostic association of a clinical diagnosis of depression in adult congenital heart disease: results of the Boston Adult Congenital Heart Disease Biobank","volume":"9","author":"Carazo","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B73","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf"},{"key":"2026091606032470600_qcag067-B74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2026091606032470600_qcag067-B75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026091606032470600_qcag067-B76","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B77","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B78","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B79","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"2026091606032470600_qcag067-B81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"2026091606032470600_qcag067-B82","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"2026091606032470600_qcag067-B83","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026091606032470600_qcag067-B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"2026091606032470600_qcag067-B85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10072-025-08680-z","article-title":"Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"47","author":"Wu","year":"2026","journal-title":"Neurol Sci"},{"key":"2026091606032470600_qcag067-B86","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B88","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026091606032470600_qcag067-B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2024.100561","article-title":"Coarctation of the aorta and accelerated atherosclerosis: a contemporary review on the burden of atherosclerotic cardiovascular disease","volume":"19","author":"Lee","year":"2025","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"2026091606032470600_qcag067-B90","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/21501351241311280","article-title":"Long-term coronary artery complications following the arterial switch operation for transposition of the great arteries\u2014a scoping review","volume":"16","author":"Lim","year":"2025","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"2026091606032470600_qcag067-B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2024.100532","article-title":"Sleep disordered breathing and adult congenital heart disease","volume":"18","author":"Vakali","year":"2024","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"2026091606032470600_qcag067-B92","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP -1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP -1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026091606032470600_qcag067-B93","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug\u2212drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"2026091606032470600_qcag067-B94","doi-asserted-by":"publisher","DOI":"10.12890\/2025_005823","article-title":"When new therapies meet old challenges: tirzepatide\u2013warfarin interaction in a mechanical mitral valve patient","volume":"12","author":"Natale","year":"2025","journal-title":"Eur J Case Rep Intern Med"},{"key":"2026091606032470600_qcag067-B95","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"Heck","year":"2000","journal-title":"Pharmacotherapy"},{"key":"2026091606032470600_qcag067-B96","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"2026091606032470600_qcag067-B97","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B98","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"2026091606032470600_qcag067-B99","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2026091606032470600_qcag067-B100","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral","year":"1998","journal-title":"J Hypertens"},{"key":"2026091606032470600_qcag067-B101","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ehjcvp\/pvaa133","article-title":"Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study","volume":"8","author":"Ardissino","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026091606032470600_qcag067-B102","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1345\/aph.1C122","article-title":"Orlistat enhances warfarin effect","volume":"37","author":"MacWalter","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2026091606032470600_qcag067-B103","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0091270003252236","article-title":"Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers","volume":"43","author":"Zhi","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2026091606032470600_qcag067-B104","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"key":"2026091606032470600_qcag067-B105","doi-asserted-by":"publisher","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2026091606032470600_qcag067-B106","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity"},{"key":"2026091606032470600_qcag067-B107","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091606032470600_qcag067-B108","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031805","article-title":"Comparison of effectiveness among different sodium-glucose cotransoporter-2 inhibitors according to underlying conditions: a network meta-analysis of randomized controlled trials","volume":"13","author":"Kani","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B109","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B110","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102664","article-title":"Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials","volume":"49","author":"Bhanushali","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2026091606032470600_qcag067-B112","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026091606032470600_qcag067-B113","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026091606032470600_qcag067-B114","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jacc.2024.02.017","article-title":"Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease","volume":"83","author":"Neijenhuis","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026091606032470600_qcag067-B115","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1017\/S1047951125000514","article-title":"Sodium-glucose cotransporter-2 inhibitor use in patients with a Fontan circulation","volume":"35","author":"Gaydos","year":"2025","journal-title":"Cardiol Young"},{"key":"2026091606032470600_qcag067-B116","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5414\/CP202157","article-title":"Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2026091606032470600_qcag067-B117","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1142003","article-title":"Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026091606032470600_qcag067-B118","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1161\/CIRCULATIONAHA.115.017202","article-title":"Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre","volume":"132","author":"Diller","year":"2015","journal-title":"Circulation"},{"key":"2026091606032470600_qcag067-B119","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2026091606032470600_qcag067-B120","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026091606032470600_qcag067-B121","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: a Meta-Analysis of the EXSCEL and FIGHT Trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"key":"2026091606032470600_qcag067-B122","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026091606032470600_qcag067-B123","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B124","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091606032470600_qcag067-B125","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure","volume":"86","author":"Kittleson","year":"2025","journal-title":"JACC"},{"key":"2026091606032470600_qcag067-B126","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/s0735-1097(23)01391-8","article-title":"Impact of obesity on outcomes of patients undergoing heart transplantation in the United States","volume":"81","author":"Verma","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026091606032470600_qcag067-B127","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.healun.2025.04.021","article-title":"Impact of obesity on long term post heart transplantation outcomes","volume":"44","author":"Kim","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"2026091606032470600_qcag067-B128","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021346","article-title":"Impact of Obesity on Heart Transplantation Outcomes","volume":"10","author":"Chouairi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026091606032470600_qcag067-B129","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijcard.2022.03.018","article-title":"Heart failure in adults with congenital heart disease","volume":"357","author":"Brida","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026091606032470600_qcag067-B130","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jchf.2024.01.006","article-title":"Dapagliflozin in Patients With a Failing Systemic Right Ventricle","volume":"12","author":"Fusco","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026091606032470600_qcag067-B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2024.100495","article-title":"Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population","volume":"15","author":"Kheiwa","year":"2024","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"2026091606032470600_qcag067-B132","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00246-023-03332-5","article-title":"Experience with SGLT2 Inhibitors in Patients with Single Ventricle Congenital Heart Disease and Fontan Circulatory Failure","volume":"46","author":"Konduri","year":"2025","journal-title":"Pediatr Cardiol"},{"key":"2026091606032470600_qcag067-B133","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1093201","article-title":"The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease","volume":"10","author":"Neijenhuis","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026091606032470600_qcag067-B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132413","article-title":"Impact of guideline directed medical therapy on myocardial function in adults with congenital heart disease","volume":"414","author":"Bright","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026091606032470600_qcag067-B135","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cardfail.2023.03.011","article-title":"Safety and Treatment Experience With Sodium\/glucose Cotransporter-2 Inhibitors in Adult Patients With Congenital Heart Disease","volume":"29","author":"Saef","year":"2023","journal-title":"J Card Fail"},{"key":"2026091606032470600_qcag067-B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101218","article-title":"Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes","volume":"47","author":"Al-Sadawi","year":"2023","journal-title":"IJC Heart Vasc"},{"key":"2026091606032470600_qcag067-B137","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf257","article-title":"Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials","author":"Cesaro","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026091606032470600_qcag067-B138","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf784.3817","article-title":"Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials","volume":"46","author":"Mansouri","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112279","article-title":"Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: a retrospective cohort study","volume":"225","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026091606032470600_qcag067-B140","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of &gt; 80,000 patients (the SGLT2i\u2014Arrhythmias and Sudden Cardiac Death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026091606032470600_qcag067-B141","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1093\/eurheartj\/eht433","article-title":"Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription","volume":"34","author":"Budts","year":"2013","journal-title":"Eur Heart J"},{"key":"2026091606032470600_qcag067-B142","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1467-789X.2006.00296.x","article-title":"The prevalence and determinants of obesity in adults with intellectual disabilities","volume":"8","author":"Melville","year":"2007","journal-title":"Obes Rev"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcag067\/68098302\/qcag067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/6\/927\/68098302\/qcag067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/6\/927\/68098302\/qcag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:03:29Z","timestamp":1789553009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/6\/927\/8656819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":142,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,16]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcag067","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,16]]}}}